CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2.
New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53.